share_log

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

Benzinga ·  Nov 5 22:39  · Ratings

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $221 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment